Merck & Co., Inc. unveiled Phase III data on 8 April showing Keytruda yielded a disease-free survival (DFS) benefit in post-surgical kidney cancer patients. The results from the KEYNOTE-564 study are the first to show benefit with a PD-1 or PD-L1 inhibitor in adjuvant renal cell carcinoma (RCC) and could set up the drug to add its second indication in the lucrative early-line setting.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?